The Board, Scientific Advisory Board and Management of IVBHL have a proven track record in using science to create new products and to bring these products to market.
For example, IVBHL’s Executive Director and Chief Medical Officer and Chair of the Scientific Advisory board, Dr David Kingston, spent over 30 years at Roche and Genentech where he played an integral role bringing over 40 new pharmaceutical products to the market.
IVBHL is of the view that by improving the bioavailability of T3s using the TransT3 and TPD platforms, an improvement in the efficacy of T3s in therapeutic indications should be possible. Invictus has chosen to target two therapeutic indications with unmet needs, Non-Alcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic SteatoHepatitis (NASH) and pancreatic cancer where T3s have shown some promising activity in animal models and clinical studies.
ABN 16 657 241 533